Decades of clinical research have demonstrated their safety and efficacy, and they are now FDA-approved specifically for chronic weight management in adults with obesity or overweight with at least one weight-related health condition
Whats more, its demographic analysis showed significant differences between the GLP-1 RA and comparator groups in factors such as age, HbA1c, body weight, BMI, duration of diabetes, sex, race, and so on, suggesting that the effect of GLP-1RAs on DR is yet controversial and that it may vary based on the specific GLP-1RA used, as well as the patients demographic and clinical characteristics
Titration schedules in phase 3 trials of long acting insulin analogues incorporated individualization to allow the clinician to increase the dose to achieve optimal benefit without causing hypoglycaemia ( The oral obesity medications The oral GLP-1 based agents approved for obesity treatment deliver substantial weight loss
If treatment stops, the weight might return
Nutraceutical compositions for the treatment or prevention of trimethylaminuria
